Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Inducible MyD88 Signaling Enhances the Anti-AML Activity of BiTE-Secreting ENG T-Cells

Abishek Vaidya, MS, Erin E Doherty, MD, Xiya Wu, Challice L. Bonifant, MD PhD, Stephen Gottschalk, MD, Mireya Paulina Velasquez, MD

Blood (2019) 134 (Supplement_1): 4441.

https://doi.org/10.1182/blood-2019-125395

Published: 2019

Journal Articles

Transgenic Expression of IL15 in CD123-Specific BiTE-Secreting Engager T-Cells Results in Improved Anti-AML Activity

Hong Mu-Mosley, MD PhD, Lauren B Ostermann, Muharrem Muftuoglu, MD, Wendy Schober, Nalini B Patel, Abishek Vaidya, MS, Challice L. Bonifant, MD PhD, Stephen Gottschalk, MD, Mireya Paulina Velasquez, MD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 3917.

https://doi.org/10.1182/blood-2019-125928

Published: 2019

Journal Articles

Myd88/CD40 Costimulation to Enhance the Antitumor Activity of CD123-ENG T-Cells for the Immunotherapy of AML

Erin Doherty, MD, Abishek Vaidya, MS, Xiya Wu, Challice L. Bonifant, MD PhD, Melinda Mata, PhD, Ann M. Leen, PhD, Stephen Gottschalk, MD, Mireya P. Velasquez, MD

Blood (2018) 132 (Supplement 1): 4075.

https://doi.org/10.1182/blood-2018-99-116817

Published: 2018

Journal Articles

IL15 Expressing CD123-Targeted Engager T-Cell Therapy for Adult Acute Myeloid Leukemia

Hong Mu, MD PhD, Huaxian Ma, MS, Abishek Vaidya, MS, Challice L. Bonifant, MD PhD, Stephen Gottschalk, MD, Mireya P. Velasquez, MD, Michael Andreeff, MD PhD

Blood (2018) 132 (Supplement 1): 2724.

https://doi.org/10.1182/blood-2018-99-116811

Published: 2018

Journal Articles

Two-Pronged Cell Therapy for B-Cell Malignancies: Engineering NK Cells to Target CD22 and Redirect Bystander T Cells to CD19

Mireya Paulina Velasquez, MD, Arpad Szoor, MD PhD, Challice L. Bonifant, MD PhD, Abishek Vaidya, Lorenzo Brunetti, MD, Michael C Gundry, BS, Robin Parihar, MD PhD, Margaret Goodell, PhD, Stephen Gottschalk, MD

Blood (2016) 128 (22): 4560.

https://doi.org/10.1182/blood.V128.22.4560.4560

Published: 2016

Journal Articles

CD123-Engager T Cells As a Novel Immunotherapeutic for AML

Challice L. Bonifant, MD PhD, David Torres, Mireya Paulina Velasquez, MD, Kota Iwahori, MD, Caroline Arber, MD, Xiao-Tong Song, PhD, Michele S. Redell, MD PhD, Stephen Gottschalk, MD

Blood (2014) 124 (21): 3762.

https://doi.org/10.1182/blood.V124.21.3762.3762

Published: 2014

NARROW

Inducible MyD88 Signaling Enhances the Anti-AML Activity of BiTE-Secreting ENG T-Cells

Transgenic Expression of IL15 in CD123-Specific BiTE-Secreting Engager T-Cells Results in Improved Anti-AML Activity

Myd88/CD40 Costimulation to Enhance the Antitumor Activity of CD123-ENG T-Cells for the Immunotherapy of AML

IL15 Expressing CD123-Targeted Engager T-Cell Therapy for Adult Acute Myeloid Leukemia

Two-Pronged Cell Therapy for B-Cell Malignancies: Engineering NK Cells to Target CD22 and Redirect Bystander T Cells to CD19

CD123-Engager T Cells As a Novel Immunotherapeutic for AML

Email alerts

ASH Publications

American Society of Hematology

Inducible MyD88 Signaling Enhances the Anti-AML Activity of BiTE-Secreting ENG T-Cells

Transgenic Expression of IL15 in CD123-Specific BiTE-Secreting Engager T-Cells Results in Improved Anti-AML Activity

Myd88/CD40 Costimulation to Enhance the Antitumor Activity of CD123-ENG T-Cells for the Immunotherapy of AML

IL15 Expressing CD123-Targeted Engager T-Cell Therapy for Adult Acute Myeloid Leukemia

Two-Pronged Cell Therapy for B-Cell Malignancies: Engineering NK Cells to Target CD22 and Redirect Bystander T Cells to CD19

CD123-Engager T Cells As a Novel Immunotherapeutic for AML

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only